MNOV Stock — MediciNova Inc

MediciNova Inc (MNOV)

Updated October 16, 2026.

MNOV is a Stock. Total return is -87.0% over the past 19.9 years, 766.4 points behind SPY at 679.4%.

MediciNova is a biopharmaceutical company developing small molecule therapeutics targeting serious diseases with unmet medical needs, including MN-166 (ibudilast) in Phase 2 trials for neurological disorders such as progressive multiple sclerosis and amyotrophic lateral sclerosis, and MN-001 (tipelukast) in Phase 2 trials for fibrotic and metabolic conditions including nonalcoholic fatty liver disease. The company does not currently distribute dividends. MediciNova may appeal to investors seeking exposure to clinical-stage biopharmaceutical development with a focus on neurological and metabolic disease treatment.

MNOV performance versus SPY

Price and return data through 2026-10-16.

Total return is -87.0% over the past 19.9 years, 766.4 points behind SPY at 679.4%. Over the past year its total return — price change plus distributions reinvested — is 13.6%. Its deepest 1-year drawdown was 58.8%.

MNOV key facts

Asset type

Stock

Asset class

Equity

Inception date

12/07/2006

Distribution frequency

None

Last close

$1.42 (as of 2026-10-16)

Market cap

$69,894,169

Average volume

79181.0

Beta

0.614

Payout ratio

0.0%

Forward P/E

8.5324

EPS

$-0.21

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MNOV risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 58.8%.

Who may consider MNOV — and who may not

It is a weaker fit for investors who need monthly cash flow (MNOV does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on MNOV

• All tickers starting with M

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions